For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc

CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont

NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE:DV) will replace Meridian Bioscience Inc. (NASD: VIVO) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 31. SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 31, 2023 S&P SmallCap 600 Addition DoubleVerify Holdings DV Inf

CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the "Merger Agreement") with SD Biosensor, Inc., ("SDB"), Columbus Holding Company ("Parent"), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent ("

CINCINNATI, Nov. 22, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2022. Fourth Quarter 2022 Highlights (Comparison to Fourth Quarter Fiscal 2021): Consolidated net revenues totaled $65.7 million, a decrease of 14% year-over-yearDiagnostics segment net revenues increased 14% year-over-year to $39.2 millionLife Science segment delivered net revenues of $26.5 million, a decrease of 37%Submitted 510(k) for Curian® Shiga Toxin assayFull Fiscal Year 2022 Highlights (Compariso

CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the third quarter ended June 30, 2022. Third Quarter Fiscal 2022 Highlights (Comparison to Third Quarter Fiscal 2021): Consolidated net revenues totaled $67.8 million, an increase of 7% year-over-yearDiagnostics segment net revenues increased 36% year-over-year to a record $42.4 millionLife Science segment delivered net revenues of $25.4 million, a decrease of 22%Third Quarter Fiscal 2022 Results (Comparison to Third Quarter Fiscal 2021)Consolidated net revenu

CINCINNATI, July 29, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it received re-authorization of its Emergency Use Authorization (EUA) for the Revogene® SARS-COV-2 molecular assay from the U.S. Food and Drug Administration (FDA).  Meridian expects to begin shipping this product before the end of its fiscal fourth quarter, ending September 30, 2022. On November 10, 2021, Meridian announced the Revogene® SARS-CoV-2 assay was granted authorization by the FDA.

Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

CINCINNATI, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary results for its third quarter of fiscal 2022. For the third quarter of fiscal 2022, preliminary unaudited net revenues are expected to be between $66 million and $69 million. The Diagnostics segment net revenues are expected to be between $41 million and $43 million. The Life Science segment net revenues are expected to be between $25 million and $26 m

CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today two new sample-specific master mixes, Lyo-Ready™ Direct DNA qPCR Stool Mix, and Lyo-Ready™ Direct RNA/DNA qPCR Stool Mix. These innovative master mixes improve the molecular detection of DNA and RNA from crude fecal specimens while allowing room temperature stabilization of diagnostic assays. Stool samples are used in many gastrointestinal diagnostic tests to screen for harmful bacteria, fun

CINCINNATI, May 26, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that its inhibitor-tolerant qPCR master mixes are ideal for the development of fast, accurate and highly sensitive qPCR monkeypox virus (monkeypox) molecular diagnostic tests. The recent outbreak of monkeypox has caused global concern due to its unprecedented rapid spread, resulting in what is feared to be the largest outbreak outside of Africa. Monkeypox is an orthopoxvirus first identified

Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed

CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  This acquisition will help

CINCINNATI, April 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, today provided preliminary net revenues results for its second quarter of fiscal 2022. Preliminary unaudited net revenues for the second quarter of fiscal 2022 are expected to be between $109 million and $113 million, above Meridian's expectations and a record for the Company. Individually, both of the Company's segments are also expected to have record net revenues in the quarter with the Diagnostics segme

CINCINNATI, Feb. 4, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the first quarter ended December 31, 2021. First Quarter Fiscal 2022 Highlights (Comparison to First Quarter Fiscal 2021): Consolidated net revenues of $88.3 million, second best in company history with both segments ahead of expectations Life Science segment delivered net revenues of $55.1 million Diagnostics segment net revenues increased 10% year-over-year to $33.2 million Launched first Lyo-Ready™ sample-specific master mix for saliva-based assays Receive

CINCINNATI, Jan. 10, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report first quarter 2022 financial results Friday, February 4, 2022. Jack Kenny, Chief Executive Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. To participate in the live call by webcast, join directly here or visit investor.meridianbioscience.com for the link. If you are unable to join the webcast, you may join by telephone.  Fr

CINCINNATI, Nov. 12, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the fourth quarter and fiscal year ended September 30, 2021. Fourth Quarter 2021 Highlights (Comparison to Fourth Quarter Fiscal 2020): Consolidated net revenues of $76.2 million, up 19% year-over-year Life Science segment delivered net revenues of $41.9 million, up 22% year-over-year Diagnostics segment net revenues increased 15% year-over-year to $34.3 million Launched Air-Dryable™ sample specific master mixes for stool, blood and urine and Air-Dryable™ LA

CINCINNATI, Oct. 14, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, will report fourth quarter and full year 2021 financial results Friday, November 12, 2021. Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will host a conference call beginning at 10:00 a.m. Eastern Time to discuss the results and answer questions. Meridian is introducing a live webcast for this and future earnings calls.  This will provide

CINCINNATI, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the third quarter ended June 30, 2021. Third Quarter 2021 Highlights (Comparison to Third Quarter Fiscal 2020):• Consolidated net revenues of $63.5 million, down 25% year-over-year, but up 31% from pre-pandemic third quarter fiscal 2019• Diagnostics segment net revenues increased 44% year-over-year to $31.2 million• Life Science segment net revenues decreased 49% year-over-year to $32.3 million• Re-Submitted Emergency Use Authorization ("EUA") with U.S. Food and Drug Administration ("FDA") for Revogene® SARS-CoV-2 assay• Launched Lyo-Ready master mixes for loop-media